Blinatumomab for leftover leukemia in children with B-ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests whether a drug called blinatumomab can clear leftover leukemia cells in children with B-cell acute lymphoblastic leukemia (B-ALL) who still have traces of disease after standard treatment. It aims to reduce the chance of relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 1 month and 18 years
- Diagnosed with B-cell acute lymphoblastic leukemia (B-ALL)
- After initial treatment, small amounts of leukemia remain in the bone marrow (MRD+)
- No leukemia in the brain or spinal cord
- No recent extensive steroid or targeted therapy use (within past month)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for children newly diagnosed with low-risk B-cell ALL. It aims to improve outcomes while reducing side effects.
This trial tests a treatment plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia (ALL) that is intermediate or high risk. The goal is to find the best way to treat the cancer and improve outcomes.
This study tests a drug called blinatumomab for people whose leukemia returns in a very early, hidden way after a stem cell transplant. The goal is to see if this drug can clear those leftover leukemia cells and help keep the disease from coming back.
This trial tests blinatumomab, an immune therapy, in young people with B-cell acute lymphoblastic leukemia (B-ALL) after their transplant or when they are getting ready for transplant. The goal is to lower the chance of the leukemia coming back by targeting remaining leukemia cells.
This trial tests the drug blinatumomab for people whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after a stem cell transplant. The goal is to see if blinatumomab can safely treat the relapse.
This trial tests a drug called blinatumomab, given after a stem cell transplant, to help prevent leukemia from coming back in people with high-risk B-cell acute lymphoblastic leukemia. It may help keep the cancer in remission for longer.
Hear when a new B-Cell Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.